生物谷報(bào)道：一項(xiàng)臨床試驗(yàn)發(fā)現(xiàn),，一種以谷氨酸調(diào)控的神經(jīng)傳遞素為靶標(biāo)的新藥能有效地治療精神分裂癥,，新成果發(fā)表在9月號(hào)的《自然—醫(yī)學(xué)》期刊上。
以前的研究反復(fù)顯示,，谷氨酸調(diào)控神經(jīng)傳遞素的變異與精神分裂癥相關(guān),，但一直缺少這種關(guān)聯(lián)性的有力證據(jù)。對(duì)精神分裂癥而言,，所有常用的處方安定藥均以多巴胺受體為靶標(biāo),。如今，Sandeep Patil和同事報(bào)告：一種特別的谷氨酸受體亞型mGlu2/3是一種選擇性激動(dòng)素,，它對(duì)精神分裂癥患者有安定作用,。
在一組雙盲、安慰劑控制的試驗(yàn)中,，他們?cè)囼?yàn)其新藥LY2140023對(duì)精神分裂癥患者的作用,，并將這種新藥的療效與最常用的安定藥奧氮平進(jìn)行了比較，奧氮平是以多巴胺受體為靶標(biāo)的精神分裂癥治療藥物,。錯(cuò)覺(jué),、幻覺(jué)、思維混亂,、社交退縮,、冷漠和情感遲鈍均是精神分裂癥患者的主要癥狀，經(jīng)過(guò)4個(gè)星期的治療后,，Patil和同事發(fā)現(xiàn),，接受LY2140023治療的患者在這些方面的表現(xiàn)有明顯提高。
目前,，多巴胺是治療精神分裂癥的唯一靶標(biāo),，新研究表明，mGlu2/3受體激動(dòng)素具有安定特性,，可成為精神分裂癥治療的第一個(gè)替代靶標(biāo),。
Figure 1 - Blockade of phencyclidine-induced hyperlocomotion by LY404039, but not by olanzapine, is dependent on expression of Grm2 and Grm3 in mice.
(a,b) LY404039 (10 mg per kg body weight subcutaneously) or saline vehicle (a) or olanzapine (1 mg per kg body weight subcutaneously.) or saline vehicle (b) were administered 30 min before phencyclidine (7.5 mg per kg body weight intraperitoneally) or saline vehicle in either wild-type mice or mice lacking expression of mGlu2/3 receptors, and motor activity (ambulations) was measured for 1 h. Data presented are mean + s.e.m. for each experiment (n = 7–8 animals per group). *P < 0.05 compared to the Vehicle/PCP control group.
原文出處：
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova, Sergey N Mosolov, Nikolai G Neznanov, Alexander M Reznik, Anatoly B Smulevich, Vladimir A Tochilov, Bryan G Johnson, James A Monn & Darryle D Schoepp
Published online: 02 September 2007; | doi:10.1038/nm1632
First paragraph | Full Text | PDF (233 KB) | Supplementary information
